View our Privacy Policy & Terms of Use
This free content is available to registered users.
Becoming a Registered User only requires your name and email address.
Introduction and Research Question / Background, Design, and Outcomes / Participants and Follow-Up / Renal Outcomes / Cardiovascular Outcomes / Safety / Summary and Implications
Speaker: Gilles R Dagenais / Rafael Diaz / Matthew C Riddle / Helen Colhoun / Hertzel C Gerstein / Jeffrey L Probstfield / Lars Rydén
Session: Once-Weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial
Congress: 79th Scientific Sessions